lianhua qingwen contraindication

LHQW is composed of 11 herbs including Forsythia suspensa (Thunb.) Lianhua Qingwen can be a complementary strategy for treating COVID-19. Identification of a pharmacological biomarker for the bioassay-based quality control of a thirteen-component TCM formula (Lianhua Qingwen) used in treating influenza A virus (H1N1) infection. For thousands of years, traditional Chinese medicine (TCM) plays an important role in treating human diseases [[9], [10], [11], [12], [13], [14]]. Res. 6 (01), 6364. Methods: Comprehensive document retrieval was performed from both English and Chinese databases. Chin. China Central Television News (2020). Literature analysis of clinical application and adverse drug reaction/event of Lianhua Qingwen capsule. the Need for Accurate Scientific Nomenclature for Plants. A total of 2,511 citations were identified, among which 1,796 irrelevant, animal studies or duplicate studies were excluded, for screen of titles and abstracts. 66 (6), 771777. [Saururaceae; Houttuyniae Botanical drug], Rheum palmatum L. [Polygonaceae; Rhei Radix et Rhizoma] (Peng et al., 2015). Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virus. Both Lian-Hua-Qing-Wen Capsule (LHQWC) and Jin-Hua-Qing . LQ15H280003), the Clinical Research Projects of Zhejiang Medical Association (No. Advances in Pharmacology and Clinical Research of Lianhua Qingwen Capsules. While the results from our study showed that LHQW has a potentially reduced incidence of adverse reactions in certain diseases and symptoms to a greater extent than conventional treatment, efficacy is an important consideration that should not be overlooked. LHQW had been proven to accelerate the improvement of acute exacerbation of COPD (AECOPD) patients, especially for the high-risk subgroup, due to the decreased release of inflammatory mediators including IL-8, TNF- , IL-17, and IL-23 [38]. For pooled studies, the incidence of adverse reactions was lower in the LHQW group than the conventional drug group (RR = 0.63, 95% CI = 0.580.69, p < 0.001). Beggs test and Eggers test detected no visible publication bias for data from pooled studies and disease evaluation. Pharmacol. Drug Discov. Due to the low quality of the clinical research, the accuracy of this conclusion needs to be conducted to verify. DerSimonian, R., and Laird, N. (1986). We would like to express our appreciation to all authors of eligible studies which were included in the current meta-analysis. (2015). Study design was done by CH and BH. Results: In total, 217 experimental studies were included. An article on telemedicine and medical news platform Dr. Lilac pointed out that there was no scientific evidence available to indicate that LHQW was effective as prophylaxis to prevent infection, nor did there exist any official government recommendation for such usage; instead, taking the drug unnecessarily carried a risk of side effects. [Lamiaceae; Pogostemonis Botanical drug] (85g), Rheum palmatum L. [Polygonaceae; Rhei Radix et Rhizoma] (51g), Rhodiola crenulata (Hook. Pharmacol. Zhi-Hui Zhang and Wen-Cheng Zhou collected literatures and made the illustration. Secondly, separate evaluations were further performed for different diseases and types of adverse reactions. There was no statistically significant difference in the incidence of adverse reactions during treatment of COVID-19 pneumonia between the LHQW group and the conventional drug group (RR = 0.51, 95% CI = 0.141.82, p = 0.297). Royal Botanic Gardens, Kew (2021). (2021). Exploring material basis and mechanism of Lianhua Qingwen prescription against coronavirus based on network pharmacology. Although the data were far from adequate, the latest advances had shown the benefits of LHQW in COVID-19, especially in combination with other antiviral drugs. aDepartment of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, PR China, bShanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200082, PR China, cShanghai TCM-Integrated Institute of Vascular Anomalies, Shanghai, 200082, PR China, dDepartment of Pharmacy, The First Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou, 310018, PR China, eDepartment of Pharmacy, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, 310018, PR China, fState Key Laboratory of Pharmaceutical Biotechnology, Department of Biotechnology and Pharmaceutical Sciences, School of Life Science, Nanjing University, Nanjing, 210023, PR China. The current meta-analysis was conducted to systematically evaluate the security of LHQW compared with conventional drug in clinical application. However, while the potential clinical efficacy of LHQW has been demonstrated in several studies (Hu et al., 2020; Wu et al., 2020; Xiao et al., 2020; Wang et al., 2021), no consensus has been reached regarding the adverse reactions associated with LHQW therapy to date. It blocked the early stages (02h) of virus infection, and reduced virus-induced nuclear factor-kappa B (NF-B) activation and the gene expression of interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-, interferon-inducible protein (IP)-10, and monocyte chemoattractant protein (MCP)-1 [24]. This review has introduced the advances of LHQW in anti-viral treatment, intending to provide ideas for the timely treatment of COVID-19 patients. National Administration of Traditional Chinese Medicine: Traditional Chinese Medicine Is Involved in a Wide Range of Treatment and Early Intervention Has Good Effects. doi:10.19803/j.1672-8629.2015.12.011, Rivera, D., Allkin, R., Obn, C., Alcaraz, F., Verpoorte, R., and Heinrich, M. (2014). Zhong Y., Zhou J., Liang N., Liu B., Lu R., He Y., Liang C., Wu J., Zhou Y., Hu M., Zhou J. Common side effects are heart palpitations, nausea, and vomiting. Jia and colleagues established a rapid ultraperformance liquid chromatography coupled with diode-array detector and quadrupole time-of-flight mass spectrometry (UPLC-DAD-QTOF-MS) to analyze the major constituents of LHQW capsule, and the results demonstrated that 12 representative compounds were quantified as chemical marker, including salidroside, chlorogenic acid, forsythoside E, cryptochlorogenic acid, amygdalin, sweroside, hyperin, rutin, forsythoside A, phillyrin, rhein, and glycyrrhizic acid [17]. The novel coronavirus disease 2019 (COVID-19) has become a matter of international concern as the disease is spreading exponentially. Two studies reported psychiatric disorders as the adverse reaction. The risk ratio (RR) and 95% confidence interval (CI) were calculated for categorical variables. While LHQW has recently been approved for marketing by CFDA, its safety is yet to be conclusively established. Trials. The trim and fill method was employed in cases where publication bias existed (Duval and Tweedie, 2000). It was found that the total effective rate of LHQW granules combined with abidor treatment (LHQW group) was significantly higher than that of abidor group (80.95 % vs 64.86 %), while the rate of severe illness was markedly lower (14.29 % vs 23.65 %) [44]. Compared with the conventional drug group, the incidence of disease recurrence was lower in the LHQW group, implied that LHQW might could regulate and enhance the immune function of the body. showed that the usual treatment in combination with LHQW capsules (4 capsules thrice daily for 14 days) had significantly higher recovery rate, and shorter median time to symptom recovery, as compared with control group [43]. System-Organ Code Retrieval Involved. Other Symptoms Sputum.Four studies reported the effects of Lianhua Qingwen and those of conventional drugs on the duration of sputum. Clinical effectiveness and case analysis in 54 NCP patients treated with Lanhuaqingwen granules. There was no statistically significant difference in the incidence of adverse reactions during treatment of hand-foot-mouth disease between the LHQW group and the conventional drug group (RR = 0.53, 95% CI = 0.221.30, p = 0.165). Vahl. First, the quality of qualified studies was generally medium, randomization procedures and blinding information were lacking in most studies. In the evaluation of treating disease, the incidence of adverse reactions during treatment of influenza A (H1N1) and influenza were lower in the LHQW group compared to the conventional drug group. Asia-Pacific Traditional Med. Pharmacol. Wang C., Horby P.W., Hayden F.G., Gao G.F. A novel coronavirus outbreak of global health concern. Lianhua Qingwen(Forsythia suspensa (Thunb.) (2016). Keywords: Lianhua Qingwen, adverse reaction, COVID-19, influenza, traditional Chinese medicine, meta-analysis, Citation: Hu C, He B, Gong F, Liang M, Zhao D and Zhang G (2022) The Adverse Reactions of Lianhua Qingwen Capsule/Granule Compared With Conventional Drug in Clinical Application: A Meta-Analysis. N. Engl. There was no statistically significant difference in the incidence of adverse reactions during treatment of rheum between the LHQW group and the conventional drug group (RR = 0.46, 95% CI = 0.121.83, p = 0.270). [Saururaceae; Houttuyniae Botanical drug], a composition of LHQW (Huang et al., 2021), that contains allergenic ingredients, such as chlorogenic acid, as well as the unstable nature of houttuyfonate, which can cause adverse reactions (Cao, 2016). (2015). However, both groups did not differ in the rate of conversion to severe cases or viral assay findings. Pract. Furthermore, we also found that LHQW group has a reduced incidence of respiratory system damage compared to the conventional drug group. The term adverse reaction represents any undesired and unintended response that occurs with normal drug use (Gallelli et al., 2002). 12 (08), 140141. doi:10.13422/j.cnki.syfjx.20201099, Ye, C., Gao, M., Lin, W., Yu, K., Li, P., and Chen, G. (2020). Fig. Wang X., Ding Y.Q. Systematic Review Registration: https://clinicaltrials.gov/, CRD-42020224180. There was no statistically significant difference in the incidence of adverse reactions during treatment of common pneumonia between the LHQW group and the conventional drug group (RR = 0.99, 95% CI = 0.791.24, p = 0.927). CONTRAINDICATIONS Uncertainty. Kunming: Kunming University of technology. [4][10], In March 2022, during the Shanghai COVID-19 outbreak, the medication was distributed en masse to residents. Due to the inclusion of Ephedra people with high blood pressure, anxiety, history of seizures, irregular heart beats, or other heart heart conditions, should avoid taking Linhua Quingwen. This study provides a basis for establishing the clinical safety profile of LHQW. Although the results obtained for influenza were consistent with our findings, the control group in this earlier study was treated with a single drug while our control groups were treated with antiviral drugs, conventional antibiotics or symptomatic therapy. Among the eight included studies on rheum therapy, six reported adverse reactions. doi:10.13412/j.cnki.zyyl.2010.06.026. [7] In the United States, the FDA is advising consumers not to purchase or use Lianhua Qingwen, stating that it has not been approved or authorized by FDA and is being misleadingly represented as safe and/or effective for the treatment or prevention of COVID-19. doi:10.1016/0197-2456(86)90046-2, Duval, S., and Tweedie, R. (2000). doi:10.11816/cn.ni.2015-134443. We observed no significant alteration in the security evaluation indexes of treatment among different diseases. ACE2, angiotensin-converting enzyme 2; ADRs, adverse drug reactions; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; AGE, advanced glycation end products; ALI, acute lung injury; COPD, chronic obstructive pulmonary disease; COVID-19, Coronavirus Disease 19; EC50, median effective concentrations; HPLC, high performance liquid chromatography; IBV, influenza B virus; IFN, interferon; IL, interleukin; LHQW, Lianhua Qingwen; LPS, lipopolysaccharide; IP, interferon-inducible protein; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; NF-B, nuclear factor-kappa B; RAGE, receptor of advanced glycation end products; SARS, Severe Acute Respiratory Syndrome; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; TCM, traditional Chinese medicine; UPLC-DAD-QTOF-MS, ultraperformance liquid chromatography coupled with diode-array detector and quadrupole time-of-flight mass spectrometry, Coronavirus, SARS-CoV-2, Lianhua Qingwen, Antiviral activity, Complementary strategy, {"type":"clinical-trial","attrs":{"text":"NCT02867358","term_id":"NCT02867358"}}. During the study, no serious adverse events were reported. Some composition of LHQW can cause damage to the stomach and intestines, supporting the possibility of injurious effects on the gastrointestinal system: for thia suspensa (Thunb.) As COVID-19 has led to serious death and lacks treatment strategies, the potential therapeutic drugs are increasingly being explored. 48 (3), 737762. In this analysis, the incidence of adverse reactions during treatment of influenza was lower in the LHQW group compared to the conventional drug group (RR = 0.74, 95% CI = 0.630.87, p < 0.001). Flow chart of the search and selection process. [19], Although the medicine has been allowed to be sold in Canada since 2012, Health Canada has cautioned against the use of the Chinese traditional medicine to prevent, treat, and cure COVID-19. After 7 days of treatment, the main TCM syndrome scores (fever, fatigue, cough, dry throat, chest tightness), C-reactive protein and procalcitonin levels in the LHQW group were significantly lower, and the white blood cell and lymphocyte counts were obviously higher than those in abidor group [44]. Language links are at the top of the page across from the title. [8] A January 2022 meta-analysis from China reports that it may cause GI discomfort, rashes and itches, dry mouth, and dizziness, but emphasizes that the effects are more common with "conventional treatment". Li H.R., Chang L.P., Wei C., Jia Z.H. conducted another single center clinical trial which was showed that seven days after treatment with LHQW granules (6g, tid) in conjunction with conventional treatment for COVID-19 patients had a total effective rate of 92.73 % accompanied by significantly reduced major symptoms including fever, cough, fatigue and chest tightness [41]. [Caprifoliaceae; Lonicerae Japonicae Flos], Gypsum Fibrosum, Isatis indigotica Fort. the contents by NLM or the National Institutes of Health. LHQW, an innovative proprietary traditional Chinese medicine used to treat influenza, was approved by the Food and Drug Administration of the United States for Phase II of clinical trial in 2015 (Ye et al., 2020). [4][7], Lianhua Qingwen should be avoided for patients with G6PD deficiency, since its active ingredient, Lonicera japonica, will lead to hemolysis to such patients. [citation needed]. A Working List of All Plant Species. Chakraborty C., Sharma A.R., Sharma G., Bhattacharya M., Lee S.S. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Emerging data have also shown its beneficial effects in treating diverse diseases such as acute respiratory infection, influenza, pneumonia, hand-foot-mouth disease, chronic obstructive pulmonary disease (COPD), as well as COVID-19 [[20], [21], [22], [23]]. It is urgent to develop effective drugs to contain and treat COVID-19. Further clinical trial showed that LHQW was superior to oseltamivir in improving the symptoms of influenza A virus infection by a meta-analysis of randomized, controlled trials [37]. doi:10.1097/MD.0000000000026059, Gallelli, L., Ferreri, G., Colosimo, M., Pirritano, D., Guadagnino, L., Pelaia, G., et al. Related tags TCM COVID-19 China A two-week clinical trial led by renowned Chinese pulmonologist Zhong Nanshan has shown that consuming the botanical TCM product Lianhua Qingwen (LH) capsules and undergoing the standard . Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. 81503129, No. 2015, 731765. doi:10.1155/2015/731765, Jin, L., Xu, Y., and Yuan, H. (2020). Our findings support the adverse reactions recorded by Yiling Pharmaceutical, and compare the incidence risk of gastrointestinal system damage and rash with the control group. Lian Hua Qing Wen capsules (LHQW) is the most effective and commonly-used clinical formula in treating respiratory infection for thousands of years in China. doi:10.13260/j.cnki.jfjtcm.012210, Jia, W., Wang, C., Wang, Y., Pan, G., Jiang, M., Li, Z., et al. The incidence of nervous system damage was lower in the LHQW group compared to the conventional drug group (RR = 0.24, 95% CI = 0.180.32, p < 0.001). J. Ethnopharmacol. Business China. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Lianhua Qingwen is a commonly used Chinese patent medicine to treat viral infection. Prof. Zhenhua Jia formulates the prescription of Lianhua Qingwen based on the theory of collateral disease, and participates in the research projects of Lianhua Qingwen against H 1 N 1 and COVID-19. The LHQW group has a reduced incidence of gastrointestinal system damage than the conventional drug group (RR = 0.83, 95% CI = 0.740.93, p = 0.002). To clarify the in vivo effects of LHQW, Gao and colleagues recently showed that LHQW could treat influenza A virus infection in H1N1 mouse model by improving pathologic alterations and body weight loss, and reducing virus replication, lung lesions as well as inflammation [19].
Is Andrea Yeager Darin Still Alive, Frontier Central School District Board Of Education, Articles L